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the functional changes after pancreatoduodenectomy are 
described in detail with suggestions for diagnosis and treat-
ment.  Copyright © 2010 S. Karger AG, Basel and IAP 
 Introduction 
 Surgery is the cornerstone of treatment with curative 
intention for patients with tumors of the pancreatic head 
and the periampullar region. Radical resection by means 
of pancreatoduodenectomy offers the only chance for 
cure. Partial pancreatoduodenectomy was introduced in 
the beginning of the 20th century by Codivilla and 
Kausch. A modification of the classical partial pancrea-
toduodenectomy as popularized by Whipple et al.  [1] is 
the pylorus-preserving pancreatoduodenectomy (PPPD), 
first described by Watson  [2] in 1944. Preserving the py-
lorus is thought to have various advantages, such as sim-
plification of the operation and improvement of postop-
erative gastrointestinal function without any negative 
oncological consequences for the patient  [3] . To date, 
three randomized studies compared the classic Whipple’s 
operation with PPPD. Two relatively small studies report-
ed that the pylorus-preserving procedure was associated 
with shorter operation time, less blood loss, less blood 
transfusion and a lower morbidity rate in comparison to 
the classic Whipple procedure  [4, 5] . In contrast, our own 
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 Abstract 
 Relatively little is known about the gastrointestinal function 
after recovery of a pancreatoduodenectomy. This review fo-
cuses on the functional changes of the stomach, duodenum 
and pancreas that occur after pancreatoduodenectomy. Al-
though the mortality in relation to pancreatoduodenecto-
my has decreased over the years, it  remains associated with 
considerable morbidity, which occurs in 40–60% of patients. 
Physical complaints early after the operation are often 
caused by motility disorders, in particular delayed gastric 
emptying, which occurs in up to 40% of patients. During lon-
ger follow-up of these patients the occurrence of endocrine 
and exocrine pancreatic insufficiency becomes more pre-
dominant. Diabetes mellitus develops in 20–50% of patients 
after a pancreatic resection (pancreatogenic diabetes). The 
main presenting symptoms of exocrine insufficiency are 
weight loss and steatorrhea. Its presence is suspected on 
clinical ground and can be supported by fecal elastase-1 
measurement. Exocrine insufficiency can be compensated 
with oral enteric-coated enzyme supplements. The quality 
of life issue will be addressed as an important outcome mea-
surement after pancreaticoduodenectomy. Furthermore, 
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randomized multicenter study  [6] found no difference 
between both procedures in operation time, blood loss, 
delayed gastric emptying, hospitalization time, or overall 
survival rate.
 In spite of the still relatively high morbidity resulting 
from the extensive and invasive surgical procedure, pan-
creatoduodenectomy is increasingly being performed. 
This is partly because of a considerable reduction in peri-
operative mortality. In high-volume centers, a mortality 
rate of less than 2% has been reported  [7–12] . Because of 
these advances, the assessment and improvement of 
short- and long-term postoperative quality of life have 
become important topics. Many publications have re-
ported on quality of life issues after pancreatoduodenec-
tomy  [2, 13–18] . However, relatively little is known about 
the gastrointestinal function after recovery of a pancre-
atoduodenectomy.
 This review focuses on the functional changes of the 
stomach, duodenum and pancreas that occur after pan-
creatoduodenectomy. The various factors and mecha-
nisms that are involved will be described with recom-
mendations for diagnosis and treatment.
In  table 1 , a summary is given of the functional chang-
es of the stomach, duodenum and pancreas after pancre-
atoduodenectomy.
 Changes in Gastric Function 
 Delayed gastric emptying (DGE) is a leading cause
of morbidity after pancreatoduodenectomy, occurring 
early after the surgical procedure with an estimated inci-
dence between 15 and 40%. DGE is defined as gastric sta-
sis requiring nasogastric intubation for ten days or more 
or the inability to tolerate a regular diet on the 14th post-
operative day  [19] . Whether or not the pylorus is pre-
served does not seem to have a great impact in the occur-
rence of delayed gastric emptying  [6] . There is a decrease 
in the subjective perception of the occurrence of belching 
and nausea after Whipple’s operation due to the absence 
of mechanoreceptors as a result of the partial stomach 
resection  [20] . Other causes of DGE after pancreatoduo-
denectomy are the presence of peritonitis as a result of 
postoperative complications such as intra-abdominal ab-
scesses, leakage of the pancreatojejunostomy, ischemia of 
the antropyloric muscles and reoperation  [21, 22] . Objec-
tive quantification of DGE is difficult. In daily practice, 
gastric scintigraphy is the preferred method to determine 
DGE. For this purpose, technetium (20 MBq 99m hepatate) 
labeled semi-solids or a technetium (20 MBq  99m Tc-
pertechnetate) labeled pancake are used. Normal half-
emptying time varies between 38 and 83 min after intake. 
In general, this investigation is considered too time con-
suming and too much of a burden for patients in the ear-
ly postoperative phase and a presumptive diagnosis is 
usually made on clinical grounds.
 Naritomi et al.  [23] showed that a low serum level of 
motilin delays gastric passage in these patients. In a ran-
domized, placebo-controlled study of 118 consecutive pa-
tients undergoing a pancreatoduodenectomy, Yeo et al. 
 [24] have shown that the administration of erythromycin, 
which has not only antimicrobial but also prokinetic ac-
tivity, stimulates gastric evacuation. They found a signifi-
cantly reduced need to reinsert a nasogastric tube and a 
Table 1. Functional changes of the stomach, duodenum and pancreas after pancreatoduodenectomy
Functional changes Incidence Presentation Diagnosis Treatment
Stomach
Delayed gastric emptying 15–40% nasogastric tube >10 days
inability to tolerate a regular
diet ≥14th day p.o.
gastric emptying
scintigraphy
recovery
<6 months
erythromycin
Duodenum
f Pancreas-stimulating hormones 100% altered digestion process failure to thrive symptomatic
Peptic ulcer formation <5% proton pump
inhibitors
Pancreas
Diabetes mellitus 20–40% hyperglycemia f glucagon
d insuline insensitivity
hormonal
regulation
Exocrine insufficiency unknown algorithm figure 1 figure 1 figure 1
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significantly reduced retention of liquids in the group of 
patients that was treated with erythromycin. Besides 
erythromycin, most commonly used prokinetics are 
metoclopramide, domperidon and cisapride with variable 
clinical relief of symptoms. The value of new prokinetics, 
including mosapride citrate (a selective agonist for 5-hy-
droxytryptamine-4 receptors), itopride hydrochloride (a 
benzamide derivative with both dopamin D2 receptor an-
tagonism and acetylcholinesterase inhibition) and GM-
611 (an erythromycin-derived motilin agonist) has not yet 
been fully investigated and therefore these drugs are not 
yet regularly used in clinical practice. In general, the gas-
tric emptying function gradually recovers spontaneously 
to the preoperative level by 6 months after PPPD.
 Changes in Duodenal Function 
 With the resection of the largest part of the duode-
num, the major digestive processes are disturbed and the 
delicately controlled digestive chain between the stom-
ach, duodenum and pancreatobiliary secretions is dis-
rupted. A reduced production of pancreas-stimulating 
hormones such as gastrin, cholecystokinin (CCK) and se-
cretin leads to an inadequate pancreatic secretion of bi-
carbonate. As a result, the gastric content is not neutral-
ized to an optimal pH. Furthermore, a reduced produc-
tion of enterokinase by the duodenum leads to an 
inadequate activation of pancreatic proteolytic, amylo-
lytic and lipolytic enzymes.
 As mentioned before, resection of the pancreatic head 
and duodenum results in a decrease in pancreas bicar-
bonate secretion and inadequate gastric acid neutraliza-
tion. Excretion of this bicarbonate-poor fluid in the rem-
nant of the duodenum stimulates the development of ul-
cerations. However, peptic ulcers occur in less than 5% of 
patients after pancreatic surgery  [25] . A possible explana-
tion could be the frequent use of octreotide and proton-
pomp inhibitors postoperatively, although controversies 
remain regarding their use after a pancreatoduodenec-
tomy.
 Changes in Endocrine Pancreatic Function 
 The more extended the resection of the pancreas, the 
greater the risk of endocrine (and exocrine) pancreatic 
insufficiency.
 The incidence of diabetes mellitus after a pancreatic 
resection varies between 20 and 50%  [26] , with some pa-
tients already suffering from diabetes preoperatively and 
a number of patients developing diabetes de novo.
 Controversy remains whether diabetes is a risk factor 
for the development of pancreatic cancer or whether pan-
creatic cancer causes diabetes. There are compelling data 
that long-standing diabetes might increase the risk of 
pancreatic cancer  [27–30] . However, in simple cross-sec-
tional studies (recent-onset) diabetes is frequently diag-
nosed in combination with pancreatic cancer. This is an 
argument against preexisting diabetes mellitus being a 
risk factor for pancreatic cancer. Probably, these observa-
tions can neither be fully explained by destruction of the 
endocrine pancreas, but rather seem to be partly the re-
sult of a remote effect of the tumor causing impaired glu-
cose metabolism. An interesting clinical observation is 
the fact that in some patients the diabetes disappears 
postoperatively  [31] .
 On the other hand, preoperative obstruction of the 
pancreatic duct is associated with the development of di-
abetes mellitus as a result of destruction of the parenchy-
ma  [32] . In our own experience  [33] patients with an iat-
rogenic pancreatic duct occlusion during a pancreatodu-
odenectomy develop significantly more diabetes mellitus 
in comparison to those who had a pancreatojejunal anas-
tomosis.
 The type of glucose intolerance which results from 
pancreatic resection is termed pancreatogenic diabetes. It 
is associated with features distinct from both type I (in-
sulin-dependent) and type II (insulin-independent, or 
adult-onset) diabetes  [34] .
 Hepatic insulin resistance with persistent endogenous 
glucose production and enhanced peripheral insulin sen-
sitivity results in a brittle form of diabetes, which can be 
difficult to manage. Surprisingly, pancreatogenic diabe-
tes is characterized by a decrease in hepatic  insulin recep-
tor availability and an increase in peripheral insulin re-
ceptor availability  [35] . This paradoxical effect is prob-
ably due to the concurrent deficiency in pancreatic 
polypeptide and renders the liver resistant to the suppres-
sant effects of insulin on hepatic glucose production. The 
result of increased hepatic glucagon responsiveness and 
diminished hepatic insulin responsiveness is elevated (or 
unsuppressed) endogenous glucose production, which in 
turn results in hyperglycemia together with an enhanced 
hypoglycemic response to exogenous insulin in patients 
with pancreatogenic diabetes.
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 Assessment of Endocrine Pancreatic Function 
 Diabetes mellitus is defined as a fasting glucose con-
centration  6 7.0 mmol/l or a random glucose value  6 11 
mmol/l  [36] or a GTT (glucose tolerance test) level  6 11 
mmol/l after 2 h.
 Treatment of Endocrine Pancreatic Insufficiency 
 Usually, the treatment of patients with diabetes starts 
with diet, weight reduction, and exercise. After a pancre-
atic resection most patients already suffer from maldiges-
tion problems.
 Patients with persistent hyperglycemia are often start-
ed on one or more oral hypoglycemic drugs. Insulin is 
added if target level of glucose is not attained. Patients 
with pancreatogenic diabetes behave differently com-
pared to other diabetics with respect to insulin therapy. 
These ‘brittle diabetics’ may become unpredictably hy-
poglycemic during maintenance insulin therapy, unre-
lated to meals or exercise. The need for insulin depends 
upon the delicate balance between insulin secretion, in-
sulin resistance and glucagon responsiveness.
 Changes in Exocrine Pancreatic Function 
 From the scant data that are available to date, it is dif-
ficult to provide an overview of the risk of exocrine insuf-
ficiency and the success or failure rate of supplementa-
tion therapy. The pathophysiology is complex and com-
prises factors such as preoperative exocrine pancreatic 
function and the chosen surgical procedure of resection 
and restoration of gastrointestinal tract continuity.
 In general, the functional reserve of exocrine pancre-
atic functions ensures that insufficiency occurs only dur-
ing the course of illness. Up to 90–95% of the pancreatic 
enzyme output may be lost before clinical signs of exo-
crine insufficiency develop  [37] .
 The most frequently described change in exocrine 
pancreatic function after pancreatoduodenectomy is re-
duced digestion of fat which leads to weight loss, nutrient 
deficiency and subjective complaints consistent with ste-
atorrhea  [38] . It is extremely difficult to appreciate and 
unravel the impact of each individual factor that contrib-
utes to the postsurgical maldigestion.
 Most of the data on exocrine pancreatic insufficiency 
after pancreatic surgery arise from studies in patients 
with chronic pancreatitis. This group of patients is known 
to develop exocrine pancreatic insufficiency frequently 
in the course of their illness due to destruction of acinar 
cells with replacement of the parenchyma by fibrous tis-
sue. Deterioration of the exocrine function often occurs 
after pancreatic surgery, partly depending on the exten-
siveness of resection.
 Another important factor regarding the exocrine 
function is whether the pancreatoduodenectomy is com-
bined with a partial resection of the stomach. First of all 
there is an inadequate grinding of food particles. Second-
ly, a reduced secretion of secretin and CCK results in a 
reduced production of bicarbonate-rich fluid and diges-
tive enzymes, such as amylase, lipase and trypsinogen, 
which are important for the continuation of the diges-
tion. Finally, the resection of the pancreatic parenchyma 
also contributes to a decreased production of pancreatic 
juices, leading to maldigestion and malabsorption of nu-
trients postoperatively.
 Although compensatory hypertrophy of the pancre-
atic remnant with increased enzyme production has been 
observed in animal research, this is hardly ever sufficient 
to compensate for the induced exocrine insufficiency in 
the clinical setting.
 The type of reconstruction after pancreatoduodenec-
tomy also appears to affect the occurrence of exocrine 
loss of function. In some studies  [39] a pancreatogastros-
tomy is described to cause further deterioration of the 
exocrine insufficiency as a result of accelerated inactiva-
tion of pancreatic enzymes by gastric juices.
 Assessment of Exocrine Pancreatic Function 
 A number of different exocrine pancreatic function 
tests are available  [40] . The secretin-cerulein intubation 
test is often used as the ‘gold standard’. This test involves 
the collection of gastric juices after intravenous adminis-
tration of secretin and measurement of luminal bicar-
bonate and protein levels. However, it is difficult or even 
impossible to perform postoperatively. Much less elabo-
rate are indirect nonintubation function tests with ad-
ministration of a pancreatic enzyme supplement and the 
measurement of the enzymatic breakdown of intralumi-
nally administered products. The most widely used tests 
for this purpose are the bentiromide or N-benzoyl- L -ty-
rosyl- p -aminobenzoic acid test (BT-PABA/PAS test) and 
the pancreolauryl (fluorescein dilaurate) test. In the ben-
tiromide test, bentiromide is broken down by chymotrip-
sin into  p -aminobenzoe acid and aminobenzoate acid, 
which is absorbed and secreted by the urine. However, 
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false-positive test results (i.e. exocrine pancreatic insuf-
ficiency is falsely diagnosed) may occur in cases of poor 
absorption due to intestinal resection, delayed gastric 
emptying or rapid intestinal transit. In the pancreolauryl 
test, fluorescein dilaurate is administered, which is also 
absorbed and secreted by the urine. Preexisting liver dis-
ease, renal insufficiency and malabsorption syndromes 
can induce false-positive results.
 For clinical practice, the fecal elastase-1 test is an ef-
fective test for the evaluation of exocrine pancreatic in-
sufficiency  [41–44] . This test has a number of advantages. 
First, the enzyme is not degraded during intestinal trans-
port; secondly, elastase is concentrated in the feces, and, 
finally, the enzyme is easily detected by means of an
ELISA test. Especially during the initial phase of exocrine 
pancreatic insufficiency this test shows high sensitivity 
and specificity. Another advantage of this test is the fact 
that the results are not affected by the use of enzyme sup-
pletion therapy.
 The cholesteryl [ 14 C]octanoate breath test is also a 
suitable indirect test for this purpose  [45, 46] . The test is 
based on the intraluminal hydrolysis of cholesteryl- 14 C-
octanoate by pancreatic cholesterol esterase and the sub-
sequent absorption and rapid metabolization of  14 C-oc-
tanoic acid to  14 CO 2 . Measurement of  14 CO 2 in breath 
allows an indirect estimation of intraluminal hydrolytic 
activity and its time course. Only pancreas-specific en-
zyme activity is measured since intraluminal activity of 
cholesterol esterase is of pancreatic origin only.
 Treatment of Exocrine Pancreatic Insufficiency 
 In clinical practice, it is recommended to supplement 
pancreas enzymes after any form of pancreatic resection. 
In several studies  [47–52] the enteric-coated (mini-)mi-
crospheres are generally the preferred pharmacological 
formulation of pancreatic enzymes. The coating with a 
pH sensitive polyacryl acid layer, which only dissolves at 
   Pancreatoduodenectomy 
   Weight loss and steatorrhea 
  Fecal elastase-1 determination 
Abnormal   Normal 
  Enzyme suppletion*    Await: weight loss and steatorrhea
Persisting complaints: weight loss/diarrhea/steatorrheaNo complaints
Continuation of dose  
Adjustment of dose Await: weight loss and steatorrhea 
No complaints Persistent complaints
Continuation of dose Adjustment of dose; start PPI
No complaints Exclude other pathology such as celiac disease,
bacterial overgrowth, etc. 
 Fig. 1. Algorithm for the diagnosis and 
treatment of exocrine  pancreatic insuffi-
ciency.  * Pancreatine preparations: start 
with 25,000–50,000 IU lipase during main 
meal and 10,000–25,000 IU lipase during 
in-between snacks. 
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a pH level  1 5.5, maintains the enzyme integrity in the 
stomach and therefore improves the efficacy of the en-
zyme supplements. For this reason, the use of a proton 
pump inhibitor postoperatively also helps to increase the 
pH in the proximal small intestine, aiding to achieve a 
rapid and proximal release of pancreatic enzymes from 
the enteric coat. The coating also masks the unpleasant 
taste of these enzymes. However, one should keep in mind 
that in patients who already suffer from impaired diges-
tion due to the partial gastric resection, the duodenum 
resection and the jejunal reconstruction, the enzyme re-
lease from these enteric-coated preparations will be too 
slow and therefore the efficacy will decrease. Therefore, 
in order to obtain an optimal therapeutic effect, it is rec-
ommended to administrate oral enzymes just after the 
meals, or even better, distributed along with meals  [53] .
In figure 1 an algorithm is suggested for diagnosis and 
treatment of pancreatic exocrine insufficiency.
 Quality of Life  
 Quality of life (QoL) is an important outcome measure 
after pancreatic resection for malignancy because vari-
ous surgical approaches aimed at prolonged survival can 
have a great impact on patient performance.
 Although many studies have addressed the QoL issue, 
it is difficult to compare QoL results because of differ-
ences in methods, study designs and patients character-
istics in these studies. The instruments used for QoL as-
sessment range from visual analogue scales, standard-
ized health care-related questionnaires in combination 
with a standard Functional Assessment of Cancer Ther-
apy Hepatobiliary QoL survey  [13] to an EORTC QLQ 
C30 core questionnaire  [16] in combination with a dis-
ease-specific Gastrointestinal QoL index  [15, 18] . Most 
studies revealed a large decrease in most QoL scales im-
mediately after surgery followed by a slow recovery to 
preoperative level by 12–24 months after surgery. The 
surgical techniques of resection and reconstruction do 
not seem to affect QoL. From a recent study by Morak et 
al. (paper accepted in June 2009 for  Cancer ), comparing 
QoL in patients receiving celiac axis infusion chemother-
apy/radiotherapy (CAI/RT) after pancreatoduodenecto-
my with QoL in patients without adjuvant treatment, 
they found that over a period of 24 months, CAI/RT im-
proved quality of life compared to observation alone in 
patients with resected pancreatic and periampullary can-
cer. However, these studies contain no information on 
patients who were operated with a palliative intention.
 Proposal for Diagnostic and Therapeutic Approach 
of Pancreatic Insufficiency 
 In all patients with a condition involving the pancreas, 
we recommend a fasting glucose level and fecal elastase-1 
determination at onset. If the results are abnormal one 
can start treatment with hormonal regulation and en-
zyme supplementation.
 Apart from decreased insulin production, the increase 
in insulin insensitivity combined with the decrease in 
glucagon production may play an important part in these 
patients. Therefore, postoperative monitoring of the glu-
cose level is of great importance in order to treat endo-
crine pancreatic insufficiency adequately.
 Enzyme supplementation can be started directly after 
resuming oral intake postoperatively. The recommended 
start doses of pancreatine capsules are 25,000 to 50,000 
IU lipase during a main meal and 10,000 to 25,000 IU li-
pase during in-between snacks. For an optimal mixture 
of food and enzymes, the ingestion of enzymes should
be divided over the meal. The efficacy of treatment is 
evaluated by means of repeated measurements of body 
weight and history takings of steatorrhea-associated 
complaints.
 Persistent weight loss and steatorrhea are indications 
of an inadequate compensation of the exocrine pancre-
atic insufficiency. In case of an insufficient treatment re-
sponse, the dosis should be increased and/or a proton-
pump inhibitor should be started. In treatment-resistant 
cases other diagnosis such as celiac disease or bacterial 
overgrowth should be considered. The efficacy of treat-
ment is evaluated by means of repeated measurements of 
body weight and history takings of steatorrhea-associat-
ed complaints. The cholesteryl [ 14 C]octanotate breath test 
can be used for monitoring.
 Conclusion 
 Motility disorders and endocrine and exocrine pan-
creatic insufficiency are frequently encountered after 
pancreatoduodenectomies. The resulting symptoms have 
a substantial impact on the patient’s quality of life. Now 
that the postoperative mortality after pancreatoduode-
nectomy has substantially decreased, more attention 
should be focussed on the diagnosis and treatment of the 
functional consequences after pancreatoduodenectomy. 
For this purpose, we have indicated a practical guide-
line.
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